NRG1 and breast carcinoma: Using primary CAFs derived from tumour tissue of luminal breast cancer patients, we demonstrate how heterogeneous expression of NRG1 in CAFs determines response of cancer cells to therapies blocking the HER3 signaling pathway [35, 36].